Summary of project PR000050
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000050. The data can be accessed directly via it's Project DOI: 10.21228/M8RG6T This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR000050 |
| Project DOI: | doi: 10.21228/M8RG6T |
| Project Title: | Small cell lung cancer metabolome |
| Project Type: | Metabolomic profiling comparison between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), to define novel biomarkers for therapy, diagnostics and early detection. |
| Project Summary: | The goal of this pilot project is to comprehensively evaluate metabolic underpinnings of small cell lung cancer (SCLC) and couple with proteome level measurements of global kinase and other enzyme level expression data to provide insight into the upstream signaling networks that may be driving the pathogenesis of SCLC. Alterations in cancer metabolism are increasingly realized as an emerging area of research and potentially offers new therapeutic strategies. As part of ongoing studies, we are employing a chemical biology platform, activity-based protein profiling (ABPP), to study the SCLC proteome. ABPP uses chemical probes that are directed against the active sites of enzymes to interrogate the functional state of enzymes in biological samples. We used ATP based probes to study differences in kinase and other ATP binding proteins between SCLC and non-small cell lung cancer (NSCLC). We used well curated lung cancer cell lines that facilitate functional analysis of key proteins and pathways. Interestingly, our preliminary data strongly implicates hyperactivated metabolic pathways in SCLC when compared to NSCLC cell lines. A strong signal of upregulated metabolic kinases and other proteins involved in glycolysis, pyruvate metabolism, and purine metabolism have been identified through this approach. However, whether the alterations in the protein levels identified through this proteomic based approach corresponds to altered levels of metabolites through metabolic pathways remains unclear. This new opportunity will allow us to profile SCLC for alterations in metabolism that can be compared to NSCLC. We will conduct metabolomics studies on our SCLC cell lines. Relationships between the underlying alterations in metabolic kinases and other signaling molecules and mechanisms promoting the aggressive phenotype of these SCLC tumors remain unclear. We will collaborate with the NIH Eastern Regional Comprehensive Metabolomics Resource Core at RTI International (RTI RCMRC) to enable metabolomic profiling and analysis of our existing cell lines and tumor tissues. |
| Institute: | H. Lee Moffitt Cancer Center |
| Department: | NCI-designated comprehensive cancer center |
| Last Name: | Haura |
| First Name: | Eric B. |
| Address: | 12902 Magnolia Drive, MRC 3 East |
| Email: | eric.haura@moffitt.org |
| Phone: | 813-745-6827 |
Summary of all studies in project PR000050
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST000052 (Availability TBA) | Small cell lung cancer metabolome (part I) | Homo sapiens | University of North Carolina | MS | - | - | 49 | Not available |
| ST000220 | Small cell lung cancer metabolome (part II) | Homo sapiens | University of North Carolina | MS | 2016-07-08 | 1 | 21 | Uploaded data (55.7G)* |
